Decreased level of peripheral CD8+CD28+ T cells is associated with lymph node metastasis in patients with breast cancer
Abstract
Background: Lymph node metastasis (LNM) is an independent risk factor for prognosis in patients with early breast cancer (EBC). Here we explored whether peripheral lymphocyte subtypes could be used as surrogate markers for LNM in patients with EBC. Materials & methods: The lymphocyte subpopulations in peripheral blood were measured in 152 EBC patients and 43 patients with benign breast tumors. Results: The cytotoxic T cell count was significantly lower in patients with EBC than in patients with benign tumors (244.17 ± 105.83 vs 289.97 ± 121.72; p = 0.02), especially in patients with LNM (218.36 ± 86.21; p = 0.04). Conclusion: A decreased level of peripheral CD8+CD28+ T lymphocytes is associated with LNM in patients with EBC and could be used as a potential therapeutic target for breast cancer.
References
- 1. . Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).
- 2. . Breast cancer prevention based on gene-environment interaction. Mol. Carcinog. 50(4), 280–290 (2011).
- 3. . Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63(1), 181–187 (1989).
- 4. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG. Nat. Med. 25(2), 312–322 (2019).
- 5. . Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
- 6. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24(7), 986–993 (2018).
- 7. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179(5), 1191–1206.e1121 (2019).
- 8. . Association between the CD28 c.17 +3 T >C polymorphism (rs3116496) and cancer risk: an updated meta-analysis. Med Sci Monit. 25, 1917–1927 (2019).
- 9. Elevated level of peripheral CD8(+)CD28(−) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Cancer Immunol. Immunother. 62(6), 1123–1130 (2013).
- 10. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann. Intern. Med. 147(8), 573–577 (2007).
- 11. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann. Oncol. 30(10), 1541–1557 (2019).
- 12. . Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat. Rev. Cancer 10(1), 2–3 (2010).
- 13. . Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 109(3), 295–299 (2002).
- 14. . CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229(1), 12–26 (2009).
- 15. . Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4(5), 336–347 (2004).
- 16. . Evolving roles for targeting CTLA-4 in cancer immunotherapy. Cell Physiol. Biochem. 47(2), 721–734 (2018).
- 17. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci. Transl. Med. 9(393), (2017).
- 18. Circulating CD8(+)CD28(−) suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: a cohort study. Cytotherapy 20(1), 126–133 (2018).
- 19. Association of CD28 IVS3 +17T/C polymorphism with soluble CD28 in rheumatoid arthritis. Dis. Markers 30(1), 25–29 (2011).
- 20. Association of CTLA4 and CD28 gene variants and circulating levels of their proteins in patients with breast cancer. In Vivo 30(4), 485–493 (2016).
- 21. . The association between CD28 gene rs3116496 polymorphism and breast cancer risk in Chinese women. Biosci. Rep. 37(6), (2017).
- 22. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318(10), 918–926 (2017).
- 23. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled Phase 3 trial. Lancet Oncol. 19(10), 1385–1393 (2018).
- 24. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382(9), 810–821 (2020).
- 25. Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173. J. Clin. Oncol. 35(Suppl. 15), S556–S556 (2017).
- 26. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing Phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 6(5) 1–9
doi:10.1001/jamaoncol.2019.6650 (.2020).